[2]
Ben Amar J, Dhahri B, Aouina H, Azzabi S, Baccar MA, El Gharbi L, Bouacha H. [Treatment of tuberculosis]. Revue de pneumologie clinique. 2015 Apr-Jun:71(2-3):122-9. doi: 10.1016/j.pneumo.2014.09.001. Epub 2014 Nov 27
[PubMed PMID: 25434510]
[3]
Parekh MJ, Schluger NW. Treatment of latent tuberculosis infection. Therapeutic advances in respiratory disease. 2013 Dec:7(6):351-6. doi: 10.1177/1753465813503028. Epub 2013 Sep 20
[PubMed PMID: 24056289]
Level 3 (low-level) evidence
[4]
Unissa AN, Subbian S, Hanna LE, Selvakumar N. Overview on mechanisms of isoniazid action and resistance in Mycobacterium tuberculosis. Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases. 2016 Nov:45():474-492. doi: 10.1016/j.meegid.2016.09.004. Epub 2016 Sep 6
[PubMed PMID: 27612406]
Level 3 (low-level) evidence
[5]
Holmes KK, Bertozzi S, Bloom BR, Jha P, Bloom BR, Atun R, Cohen T, Dye C, Fraser H, Gomez GB, Knight G, Murray M, Nardell E, Rubin E, Salomon J, Vassall A, Volchenkov G, White R, Wilson D, Yadav P. Tuberculosis. Major Infectious Diseases. 2017 Nov 3:():
[PubMed PMID: 30212088]
[7]
Moadebi S, Harder CK, Fitzgerald MJ, Elwood KR, Marra F. Fluoroquinolones for the treatment of pulmonary tuberculosis. Drugs. 2007:67(14):2077-99
[PubMed PMID: 17883288]
[8]
Mase S, Chorba T, Parks S, Belanger A, Dworkin F, Seaworth B, Warkentin J, Barry P, Shah N. Bedaquiline for the Treatment of Multidrug-resistant Tuberculosis in the United States. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2020 Aug 14:71(4):1010-1016. doi: 10.1093/cid/ciz914. Epub
[PubMed PMID: 31556947]
[9]
Andrei S, Droc G, Stefan G. FDA approved antibacterial drugs: 2018-2019. Discoveries (Craiova, Romania). 2019 Dec 31:7(4):e102. doi: 10.15190/d.2019.15. Epub 2019 Dec 31
[PubMed PMID: 32309620]
[10]
Riccardi N, Del Puente F, Magnè F, Taramasso L, Di Biagio A. Bedaquiline: A New Hope for Shorter and Better Anti-Tuberculosis Regimens. Recent patents on anti-infective drug discovery. 2018:13(1):3-11. doi: 10.2174/1574891X12666170619101904. Epub
[PubMed PMID: 28625141]
[11]
Chang KC, Yew WW. Management of difficult multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: update 2012. Respirology (Carlton, Vic.). 2013 Jan:18(1):8-21. doi: 10.1111/j.1440-1843.2012.02257.x. Epub
[PubMed PMID: 22943408]
[12]
Dheda K, Chang KC, Guglielmetti L, Furin J, Schaaf HS, Chesov D, Esmail A, Lange C. Clinical management of adults and children with multidrug-resistant and extensively drug-resistant tuberculosis. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2017 Mar:23(3):131-140. doi: 10.1016/j.cmi.2016.10.008. Epub 2016 Oct 15
[PubMed PMID: 27756712]
[13]
White RJ, Lancini GC, Silvestri LG. Mechanism of action of rifampin on Mycobacterium smegmatis. Journal of bacteriology. 1971 Nov:108(2):737-41
[PubMed PMID: 4942761]
[15]
Nakamura Y, Yura T. Effects of rifampicin on synthesis and functional activity of DNA-dependent RNA polymerase in Escherichia coli. Molecular & general genetics : MGG. 1976 Jun 15:145(3):227-37
[PubMed PMID: 781514]
[16]
De La Iglesia AI, Morbidoni HR. [Mechanisms of action of and resistance to rifampicin and isoniazid in Mycobacterium tuberculosis: new information on old friends]. Revista Argentina de microbiologia. 2006 Apr-Jun:38(2):97-109
[PubMed PMID: 17037259]
[17]
Dillon NA, Peterson ND, Feaga HA, Keiler KC, Baughn AD. Anti-tubercular Activity of Pyrazinamide is Independent of trans-Translation and RpsA. Scientific reports. 2017 Jul 21:7(1):6135. doi: 10.1038/s41598-017-06415-5. Epub 2017 Jul 21
[PubMed PMID: 28733601]
[18]
Zhang Y, Shi W, Zhang W, Mitchison D. Mechanisms of Pyrazinamide Action and Resistance. Microbiology spectrum. 2013:2(4):1-12
[PubMed PMID: 25530919]
[19]
Goude R, Amin AG, Chatterjee D, Parish T. The arabinosyltransferase EmbC is inhibited by ethambutol in Mycobacterium tuberculosis. Antimicrobial agents and chemotherapy. 2009 Oct:53(10):4138-46. doi: 10.1128/AAC.00162-09. Epub 2009 Jul 13
[PubMed PMID: 19596878]
[20]
Vianna JF, S Bezerra K, I N Oliveira J, Albuquerque EL, Fulco UL. Binding energies of the drugs capreomycin and streptomycin in complex with tuberculosis bacterial ribosome subunits. Physical chemistry chemical physics : PCCP. 2019 Sep 21:21(35):19192-19200. doi: 10.1039/c9cp03631h. Epub 2019 Aug 22
[PubMed PMID: 31436279]
[21]
Prokhorova I, Altman RB, Djumagulov M, Shrestha JP, Urzhumtsev A, Ferguson A, Chang CT, Yusupov M, Blanchard SC, Yusupova G. Aminoglycoside interactions and impacts on the eukaryotic ribosome. Proceedings of the National Academy of Sciences of the United States of America. 2017 Dec 19:114(51):E10899-E10908. doi: 10.1073/pnas.1715501114. Epub 2017 Dec 5
[PubMed PMID: 29208708]
[22]
Luan G, Drlica K. Fluoroquinolone-Gyrase-DNA Cleaved Complexes. Methods in molecular biology (Clifton, N.J.). 2018:1703():269-281. doi: 10.1007/978-1-4939-7459-7_19. Epub
[PubMed PMID: 29177748]
[23]
API Consensus Expert Committee. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations. The Journal of the Association of Physicians of India. 2006 Mar:54():219-34
[PubMed PMID: 16800350]
Level 3 (low-level) evidence
[24]
Boeree MJ, Heinrich N, Aarnoutse R, Diacon AH, Dawson R, Rehal S, Kibiki GS, Churchyard G, Sanne I, Ntinginya NE, Minja LT, Hunt RD, Charalambous S, Hanekom M, Semvua HH, Mpagama SG, Manyama C, Mtafya B, Reither K, Wallis RS, Venter A, Narunsky K, Mekota A, Henne S, Colbers A, van Balen GP, Gillespie SH, Phillips PPJ, Hoelscher M, PanACEA consortium. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. The Lancet. Infectious diseases. 2017 Jan:17(1):39-49. doi: 10.1016/S1473-3099(16)30274-2. Epub 2016 Oct 26
[PubMed PMID: 28100438]
Level 1 (high-level) evidence
[25]
Fan YL, Wu JB, Cheng XW, Zhang FZ, Feng LS. Fluoroquinolone derivatives and their anti-tubercular activities. European journal of medicinal chemistry. 2018 Feb 25:146():554-563. doi: 10.1016/j.ejmech.2018.01.080. Epub 2018 Jan 31
[PubMed PMID: 29407980]
[26]
Lobue P, Menzies D. Treatment of latent tuberculosis infection: An update. Respirology (Carlton, Vic.). 2010 May:15(4):603-22. doi: 10.1111/j.1440-1843.2010.01751.x. Epub 2010 Apr 7
[PubMed PMID: 20409026]
[27]
Schonell M, Dorken E, Grzybowski S. Rifampin. Canadian Medical Association journal. 1972 Apr 8:106(7):783-6
[PubMed PMID: 4622757]
[28]
Baciewicz AM, Chrisman CR, Finch CK, Self TH. Update on rifampin, rifabutin, and rifapentine drug interactions. Current medical research and opinion. 2013 Jan:29(1):1-12. doi: 10.1185/03007995.2012.747952. Epub 2012 Nov 30
[PubMed PMID: 23136913]
Level 3 (low-level) evidence
[30]
Pham AQ, Doan A, Andersen M. Pyrazinamide-induced hyperuricemia. P & T : a peer-reviewed journal for formulary management. 2014 Oct:39(10):695-715
[PubMed PMID: 25336865]
[31]
Chamberlain PD, Sadaka A, Berry S, Lee AG. Ethambutol optic neuropathy. Current opinion in ophthalmology. 2017 Nov:28(6):545-551. doi: 10.1097/ICU.0000000000000416. Epub
[PubMed PMID: 28759559]
Level 3 (low-level) evidence
[32]
Wargo KA, Edwards JD. Aminoglycoside-induced nephrotoxicity. Journal of pharmacy practice. 2014 Dec:27(6):573-7. doi: 10.1177/0897190014546836. Epub 2014 Sep 7
[PubMed PMID: 25199523]
[33]
Stephenson AL, Wu W, Cortes D, Rochon PA. Tendon Injury and Fluoroquinolone Use: A Systematic Review. Drug safety. 2013 Sep:36(9):709-21. doi: 10.1007/s40264-013-0089-8. Epub
[PubMed PMID: 23888427]
Level 1 (high-level) evidence
[34]
Inoue T, Ikeda N, Kurasawa T, Sato A, Nakatani K, Ikeda T, Yoshimatsu H. [Hyperuricemia and arthralgia during pyrazinamide treatment]. Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society. 1999 Feb:37(2):115-8
[PubMed PMID: 10214039]
[35]
Şişmanlar T, Aslan AT, Budakoğlu I. Is Hyperuricemia Overlooked when Treating Pediatric Tuberculosis Patients with Pyrazinamide? Journal of tropical pediatrics. 2015 Oct:61(5):351-6. doi: 10.1093/tropej/fmv042. Epub 2015 Jul 1
[PubMed PMID: 26136257]
[36]
Cao J, Mi Y, Shi C, Bian Y, Huang C, Ye Z, Liu L, Miao L. First-line anti-tuberculosis drugs induce hepatotoxicity: A novel mechanism based on a urinary metabolomics platform. Biochemical and biophysical research communications. 2018 Mar 4:497(2):485-491. doi: 10.1016/j.bbrc.2018.02.030. Epub 2018 Feb 15
[PubMed PMID: 29454961]
[37]
Fabrizii V, Thalhammer F, Hörl WH. [Aminoglycoside-induced nephrotoxicity]. Wiener klinische Wochenschrift. 1997 Nov 14:109(21):830-5
[PubMed PMID: 9454436]